The hope is that slamming multiple defective genes at once with highly targeted drugs will increase the chance of long-lasting remissions or even cures.
The goal is to move from having to merely tweak the proteins that are used as biotech drugs to being able to design them, even taking material from multiple organisms and using them to create new, functional genes.